An open-label study of rabeprazole in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 10, 2006, Pages 1439-1444

  Morocutti, A ^a   Merrouche, M ^b   Bjaaland, T ^c   Humphries, T ^a   Mignon, M ^b  

^a EISAI CO LTD   (Japan)

^b BICHAT HOSPITAL   (France)

^c Science for Organizations Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LANSOPRAZOLE; OMEPRAZOLE; RABEPRAZOLE; RANITIDINE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENTEROCHROMAFFIN CELL; FEMALE; HEARTBURN; HUMAN; IDIOPATHIC DISEASE; MALE; NAUSEA; PRIORITY JOURNAL; STOMACH ACID SECRETION; STOMACH BIOPSY; TREATMENT RESPONSE; VOMITING; ZOLLINGER ELLISON SYNDROME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ADULT; AGED; ANTACIDS; ENZYME INHIBITORS; FEMALE; GASTRIC ACID; HUMANS; MALE; MIDDLE AGED; ZOLLINGER-ELLISON SYNDROME;

EID: 33750456220     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03137.x     Document Type: Article

References (20)

1. Mignon M, Jensen RT (eds). Endocrine tumors of the pancreas. Recent advances in research and management. Front Gastrointest Res Basel: Karger, 1995: 23.
2. Melvin WS, Johnson JA, Sparks J, Innes JT, Ellison EC. Long-term prognosis of Zollinger-Ellison syndrome in multiple endocrine neoplasia. Surgery 1993; 114: 1183-8.
3. Farley DR, van Heerden JA, Grant CS, Miller LJ, Ilstrup DM. The Zollinger-Ellison syndrome. A collective surgical experience. Ann Surg 1992; 215: 561-9; discussion 569-70.
4. Norton JA, Doppman JL, Jensen RT. Curative resection in Zollinger-Ellison syndrome. Results of a 10-year prospective study. Ann Surg 1992; 215: 8-18.
5. Alexander HR, Bartlett DL, Venzon DJ, et al. Analysis of factors associated with long-term (five or more years) cure in patients undergoing operation for Zollinger-Ellison syndrome. Surgery 1998; 124: 1160-6.
6. Collen MJ, Jensen RT. Idiopathic gastric acid hypersecretion. Comparison with Zollinger-Ellison syndrome. Dig Dis Sci 1994; 39: 1434-40.
7. Hirschowitz BI, Simmons J, Mohnen J. Long-term lansoprazole control of gastric acid and pepsin secretion in ZE and non-ZE hypersecretors: a prospective 10-year study. Aliment Pharmacol Ther 2001; 15: 1795-806.
8. Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. Dig Dis Sci 1991; 36: 394-404.
9. Metz DC, Strader DB, Orbuch M, Koviack PD, Feigenbaum KM, Jensen RT. Use of omeprazole in Zollinger-Ellison syndrome: a prospective nine-year study of efficacy and safety. Aliment Pharmacol Ther 1993; 7: 597-610.
10. Jensen RT, Metz DC, Koviack PD, Feigenbaum KM. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Aliment Pharmacol Ther 1993; 7 (Suppl. 1): 41-50; discussion 61-6.
11. Metz DC, Pisegna JR, Ringham GL, et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci 1993; 38: 245-56.
12. Mignon M, Hochlaf S, Forestier S, Ruszniewski P, Vatier J, Joubert-Collin M. Dose-response effect of lansoprazole in patients with Zollinger-Ellison syndrome. Gastroenterol Clin Biol 1994; 18: 13-6.
13. Pisegna JR. The effect of Zollinger-Ellison syndrome and neuropeptide-secreting tumors on the stomach. Curr Gastroenterol Rep 1999; 1: 511-7.
14. Ramdani A, Mignon M, Samoyeau R. Effect of pantoprazole vs. other proton pump inhibitors on 24-hour intragastric pH and basal acid output in Zollinger-Ellison syndrome. Gastroenterol Clin Biol 2002; 26: 355-9.
15. Richardson P, Hawkey CJ, Stack WA. Proton pump inhibitors. Pharmacology and rationale for use in gastrointestinal disorders. Drugs 1998; 56: 307-35.
16. Horn J. The proton-pump inhibitors: similarities and differences. Clin Ther 2000; 22: 266-80.
17. Byrne MF, Murray FE. Formulary management of proton pump inhibitors. Pharmacoeconomics 1999; 16: 225-46.
18. Thomson AB. Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole, and rabeprazole. Curr Gastroenterol Rep 2000; 2: 482-93.
19. Welage LS, Berardi RR. Evaluation of omeprazole, lansoprazole, pantoprazole, and rabeprazole in the treatment of acid-related diseases. J Am Pharm Assoc 2000; 40: 52-62.
20. Thjodleifsson B, Cockburn I. Review article: Rabeprazole's tolerability profile in clinical trials. Aliment Pharmacol Ther 1999; 13 (Suppl. 5): 17-23.